山东步长制药股份有限公司关于子公司部分药品在国家组织集采药品协议期满品种接续采购中拟中选的公告

Group 1 - The company announced that its subsidiaries participated in a national centralized procurement process, with some products expected to be selected for procurement [1] - The procurement period for the selected products will last until December 31, 2028, and the company is unable to calculate the supply quantity at this time [1] - If the selected products are confirmed and contracts are signed, it will positively impact the company's sales, market share, and brand influence [2] Group 2 - The company approved a share repurchase plan on January 16, 2026, with a maximum repurchase price of 23.98 yuan per share and a minimum repurchase amount of 60 million yuan [6] - As of February 11, 2026, the company has repurchased a total of 6,856,400 shares, representing 0.65% of the total share capital, with a total expenditure of approximately 118.54 million yuan [7] - The repurchase will not significantly affect the company's operations, financial status, or future development, and the share distribution will still meet listing requirements [8]